Investorideas.com - Biotechnology Stock News; Seattle Genetics (Nasdaq: SGEN) and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lym
Category: Investment, Biotech
Subscribe to Investor Ideas Newswire
Visit this company: www.seattlegenetics.com
BOTHELL, Wash. & CAMBRIDGE, Mass. - September 27, 2010 (www.investorideas.com newswire, www.biotechindustrystocks.com) - Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced positive top-line results from the pivotal trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
Seventy-five percent of patients in the pivotal trial achieved an objective response as assessed by an independent central review, the primary endpoint of the trial. The median duration of response was greater than six months. The safety profile of brentuximab vedotin in this trial was generally consistent with prior clinical trial experience. A more complete data set will be presented at an upcoming scientific meeting.
"We are extremely excited with the top-line results, as they move us one step closer to our goal of bringing brentuximab vedotin to patients with relapsed or refractory Hodgkin lymphoma," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We are positioned for a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) in the first half of 2011. In addition, we plan to report top-line data from our phase II trial of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) within the next few weeks."
"The lack of adequate therapies for the treatment of relapsed and refractory Hodgkin lymphoma represents a substantial unmet medical need worldwide, with almost a third of the 30,000 newly diagnosed patients relapsing or becoming refractory to front-line therapy annually," said Nancy Simonian, M.D., Chief Medical Officer of Millennium. "These data have the potential to provide an important advance in therapy for Hodgkin lymphoma. We intend to discuss these results with European regulators to support our goal of submitting a Marketing Authorization Application to the European Medicines Agency (EMA) in 2011."
Pivotal Trial Design
The single-arm pivotal trial assessed efficacy and safety of single-agent brentuximab vedotin in relapsed or refractory, post-autologous stem cell transplant (ASCT) HL patients. Patients received 1.8 milligrams per kilogram of brentuximab vedotin every three weeks for up to 16 total doses. The primary endpoint of the trial was objective response rate as assessed by an independent review facility. Response assessments were based on the rigorous and internationally established Revised Response Criteria for Malignant Lymphoma (Cheson, 2007). Secondary endpoints included complete response rate, duration of response, progression-free survival, overall survival and tolerability. The trial was conducted under a Special Protocol Assessment (SPA) with the FDA and was discussed with the EMA during the process of obtaining EU Centralized Scientific Advice on the brentuximab vedotin development program. Brentuximab vedotin has been granted orphan drug designation by the FDA and EMA for the treatment of HL and ALCL and has been granted fast track designation by the FDA for HL.
About Brentuximab Vedotin
Brentuximab vedotin is an ADC comprising an anti-CD30 monoclonal antibody attached by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE) utilizing Seattle Genetics’ proprietary technology. The ADC employs a novel linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. This approach is intended to spare non-targeted cells and thus may help minimize the potential toxic effects of traditional chemotherapy while allowing for the selective targeting of CD30-expressing cancer cells, thus potentially enhancing the antitumor activity.
In addition to the pivotal HL trial, Seattle Genetics and Millennium are conducting a phase II trial for relapsed and refractory systemic ALCL, a phase III clinical trial (the AETHERA trial) for patients at high risk of residual HL following autologous stem cell transplant, a phase II retreatment trial for relapsed patients who previously responded to brentuximab vedotin, and a phase I combination trial for front-line treatment of HL.
About Hodgkin Lymphoma
Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen.
According to the American Cancer Society, approximately 8,500 cases of Hodgkin lymphoma will be diagnosed in the United States during 2010 and more than 1,300 will die from the disease. Globally, there are more than 30,000 cases of Hodgkin lymphoma diagnosed each year. Although front-line combination chemotherapy can result in durable response rates, up to 30 percent of these patients relapse or are refractory to front-line treatment and have few therapeutic options beyond ASCT.
About the Seattle Genetics/Millennium Collaboration
Seattle Genetics and Millennium are jointly developing brentuximab vedotin. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize brentuximab vedotin in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for brentuximab vedotin on a 50:50 basis, except in Japan where the Takeda Group will be solely responsible for development costs.
Conference Call Details
Seattle Genetics' management will host a conference call and webcast to discuss this announcement. The event will be held today at 5:30 a.m. Pacific Time (PT); 8:30 a.m. Eastern Time (ET). The live event will be available from Seattle Genetics' website at http://www.seattlegenetics.com, under the Investors and News section, or by calling (877) 941-8631 (domestic) or (480) 629-9819 (international). The access code is 4369251. A replay of the discussion will be available beginning at approximately 7:00 a.m. PT today from Seattle Genetics' website or by calling (800) 406-7325 (domestic) or (303) 590-3030 (international), using access code 4369251. The telephone replay will be available until 5:00 p.m. PT on Friday, October 1, 2010.
About Seattle Genetics
Seattle Genetics is a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin, is being evaluated in a variety of lymphoma treatment settings including the relapsed and refractory Hodgkin lymphoma indication for which top-line pivotal data have been reported. In addition, Seattle Genetics has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, MedImmune, a subsidiary of AstraZeneca, Millennium: The Takeda Oncology Company and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
For Seattle Genetics: Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential therapeutic benefit of brentuximab vedotin and plans for filing for regulatory approval with and obtaining regulatory approval from the FDA and the EMA. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include that the safety and/or efficacy results of the pivotal trial in relapsed or refractory Hodgkin lymphoma will not be sufficient to gain marketing approval in the United States or any other country, that we will be required to amend our submission for marketing approval or that such submission will be refused. In addition, our regulatory plans may change as a result of consultation with the FDA or EMA. More information about the risks and uncertainties faced by Seattle Genetics is contained in the company’s 10-Q for the quarter ended June 30, 2010 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Seattle Genetics, Inc.Peggy Pinkston, 425-527-4160ppinkston@seagen.com
or
MillenniumLauren Musto, 617-551-7848lauren.musto@mpi.com
Published at (www.investorideas.com newswire, www.biotechindustrystocks.com - leaders in sector research including biotech stocks. Visit the biotech stocks directory for more info and research:
Other top biotech news
Biotech Stock Alert; (OTCBB: UVFT) Reports Air Purifier Technology Fights Superbugs NDM-1Trading Alert: Biotech Stocks To Watch; (OTCBB: UVFT), (OTCBB: KBLB), (NASDAQ:AMGN), (NYSE:ELN)
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Monday, September 27, 2010
Investorideas.com - Biotech Stock Alert; (OTCBB: UVFT) Reports Air Purifier Technology Fights Superbugs NDM-1
Investorideas.com - Biotech Stock Alert; (OTCBB: UVFT) Reports Air Purifier Technology Fights Superbugs NDM-1
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - September 27, 2010 (Investorideas.com newswire, http://www.biotechindustrystocks.com/ ) – Biotechnology Company News- UV Flu Technologies, Inc. ( OTC.BB:UVFT ) recently announced news that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
Dr. Wladyslaw Jan Kowalski, PE, Phd, a world leading expert on the bacteria killing efficacy of ultraviolet light, recently commented on the UV-400: "Ultraviolet germicidal irradiation (UVGI) destroys bacteria by damaging the nucleic acids and thereby preventing reproduction. Multidrug-resistant microbes (superbugs) may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant. The number of multidrug resistant microbes has been increasing, apparently due to overuse of antibiotics and other factors, and is expected to pose a serious challenge to health care facilities in the future as treatment options diminish."
Dr. Kowalski further added, "The ViraTech UV-400 model air cleaner has a demonstrated ability to disinfect air and inactivate a wide range of bacterial pathogens including Staphylococcus aureus (MRSA), Pseudomonas, and Klebsiella as has been conclusively demonstrated in independent laboratory tests. The UV-400 produces a germicidal UV exposure dose of 41 J/m(2), as independently verified by biodosimetric testing, which is sufficient to reduce pathogenic bacterial populations by at least 99%. This disinfection rate will apply regardless of the multidrug resistance of bacteria such as those that may contain the NDM-1 enzyme (the superbug gene). The ViraTech UV-400 unit provides a viable option for health care facilities struggling to cope with the growing problem of multidrug resistant organisms and this technology can serve as an adjunct to existing infection management procedures and disinfection protocols wherever the potential exists for microorganisms to spread by the airborne route."
"Our Company receives reports from around the world on an almost daily basis about the growing problems connected with the spread of these increasingly drug resistant bacterial strains," said Jack Lennon, President of UV Flu Technologies. "Antibiotics have become so pervasive in today's medical therapies, that not only are they becoming less effective, but their overuse is increasingly being considered as part of the problem. Drug-resistant superbugs have now been found in 20 states, as well as worldwide, and when they hit the critically ill, they can be fatal 30-60% of the time. In one recent incident at an infant ward at the University College Hospital in London, 15 babies in the unit were found to be carrying several types of bacteria, including 13 who had bacterial superbugs resistant to treatment. Of four babies seriously infected, one survived."
"So that the public can participate in actions to help reduce the spread of these strains, the Company has committed to advertising, including television and other media in order to educate consumers and to offer help where needed," said Mr. Lennon. "We are looking to develop a plan to offer our UV-400 indoor air quality units either free or at significantly discounted costs to those schools and hospitals that suffer from serious outbreaks. We hope to partner with institutions which are genuinely interested in working with us in order to develop an action plan for their facilities. For those with respiratory problems or weakened immune systems, hospital or institution acquired bacterial infections can prove deadly. We believe our product delivers an immediate, effective and proven ability to kill at least 99% of airborne bacteria thereby reducing the risk of infection."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.John J. Lennon, President & CEO
Contact:Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838
Published at Investorideas.com and http://www.biotechindustrystocks.com/
Related industry commentary:
According to a recent article in Stltoday.com "The only antibiotics shown to work against NDM-1 are older-generation drugs that can have toxic side effects on a patient's kidneys. The drugs apparently work against the infections because they have not been circulating in the population for decades.Infection experts say new antibiotics are desperately needed to combat the growing field of superbugs.The Infectious Diseases Society of America has launched a "bad bugs need drugs" campaign to promote the development of 10 new antibiotics by 2020. The closest new antibiotic in development is still at least 18 months away from the market, Moenster said." Source: http://www.stltoday.com/lifestyles/health-med-fit/fitness/article_d0e57e62-22dc-55c7-96e1-300a858994f6.html
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Visit this company: http://www.uvflutech.com/
CENTERVILLE, MA - September 27, 2010 (Investorideas.com newswire, http://www.biotechindustrystocks.com/ ) – Biotechnology Company News- UV Flu Technologies, Inc. ( OTC.BB:UVFT ) recently announced news that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
Dr. Wladyslaw Jan Kowalski, PE, Phd, a world leading expert on the bacteria killing efficacy of ultraviolet light, recently commented on the UV-400: "Ultraviolet germicidal irradiation (UVGI) destroys bacteria by damaging the nucleic acids and thereby preventing reproduction. Multidrug-resistant microbes (superbugs) may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant. The number of multidrug resistant microbes has been increasing, apparently due to overuse of antibiotics and other factors, and is expected to pose a serious challenge to health care facilities in the future as treatment options diminish."
Dr. Kowalski further added, "The ViraTech UV-400 model air cleaner has a demonstrated ability to disinfect air and inactivate a wide range of bacterial pathogens including Staphylococcus aureus (MRSA), Pseudomonas, and Klebsiella as has been conclusively demonstrated in independent laboratory tests. The UV-400 produces a germicidal UV exposure dose of 41 J/m(2), as independently verified by biodosimetric testing, which is sufficient to reduce pathogenic bacterial populations by at least 99%. This disinfection rate will apply regardless of the multidrug resistance of bacteria such as those that may contain the NDM-1 enzyme (the superbug gene). The ViraTech UV-400 unit provides a viable option for health care facilities struggling to cope with the growing problem of multidrug resistant organisms and this technology can serve as an adjunct to existing infection management procedures and disinfection protocols wherever the potential exists for microorganisms to spread by the airborne route."
"Our Company receives reports from around the world on an almost daily basis about the growing problems connected with the spread of these increasingly drug resistant bacterial strains," said Jack Lennon, President of UV Flu Technologies. "Antibiotics have become so pervasive in today's medical therapies, that not only are they becoming less effective, but their overuse is increasingly being considered as part of the problem. Drug-resistant superbugs have now been found in 20 states, as well as worldwide, and when they hit the critically ill, they can be fatal 30-60% of the time. In one recent incident at an infant ward at the University College Hospital in London, 15 babies in the unit were found to be carrying several types of bacteria, including 13 who had bacterial superbugs resistant to treatment. Of four babies seriously infected, one survived."
"So that the public can participate in actions to help reduce the spread of these strains, the Company has committed to advertising, including television and other media in order to educate consumers and to offer help where needed," said Mr. Lennon. "We are looking to develop a plan to offer our UV-400 indoor air quality units either free or at significantly discounted costs to those schools and hospitals that suffer from serious outbreaks. We hope to partner with institutions which are genuinely interested in working with us in order to develop an action plan for their facilities. For those with respiratory problems or weakened immune systems, hospital or institution acquired bacterial infections can prove deadly. We believe our product delivers an immediate, effective and proven ability to kill at least 99% of airborne bacteria thereby reducing the risk of infection."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.John J. Lennon, President & CEO
Contact:Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838
Published at Investorideas.com and http://www.biotechindustrystocks.com/
Related industry commentary:
According to a recent article in Stltoday.com "The only antibiotics shown to work against NDM-1 are older-generation drugs that can have toxic side effects on a patient's kidneys. The drugs apparently work against the infections because they have not been circulating in the population for decades.Infection experts say new antibiotics are desperately needed to combat the growing field of superbugs.The Infectious Diseases Society of America has launched a "bad bugs need drugs" campaign to promote the development of 10 new antibiotics by 2020. The closest new antibiotic in development is still at least 18 months away from the market, Moenster said." Source: http://www.stltoday.com/lifestyles/health-med-fit/fitness/article_d0e57e62-22dc-55c7-96e1-300a858994f6.html
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Info:
Published at http://www.investorideas.com/ - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Friday, September 24, 2010
Biotechnology Products; UV Flu Technologies (OTC.BB: UVFT) UV-400 Air Purifier Fights Superbugs including NDM-1
Biotechnology Products; UV Flu Technologies (OTC.BB: UVFT) UV-400 Air Purifier Fights Superbugs including NDM-1
"Superbugs may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant"- Dr. Wladyslaw Jan Kowalski, PE, Phd
CENTERVILLE, MA--(Investorideas.com newswire ) - UV Flu Technologies, Inc. (OTC.BB:UVFT ) reports that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
Dr. Wladyslaw Jan Kowalski, PE, Phd, a world leading expert on the bacteria killing efficacy of ultraviolet light, recently commented on the UV-400: "Ultraviolet germicidal irradiation (UVGI) destroys bacteria by damaging the nucleic acids and thereby preventing reproduction. Multidrug-resistant microbes (superbugs) may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant. The number of multidrug resistant microbes has been increasing, apparently due to overuse of antibiotics and other factors, and is expected to pose a serious challenge to health care facilities in the future as treatment options diminish."
Dr. Kowalski further added, "The ViraTech UV-400 model air cleaner has a demonstrated ability to disinfect air and inactivate a wide range of bacterial pathogens including Staphylococcus aureus (MRSA), Pseudomonas, and Klebsiella as has been conclusively demonstrated in independent laboratory tests. The UV-400 produces a germicidal UV exposure dose of 41 J/m(2), as independently verified by biodosimetric testing, which is sufficient to reduce pathogenic bacterial populations by at least 99%. This disinfection rate will apply regardless of the multidrug resistance of bacteria such as those that may contain the NDM-1 enzyme (the superbug gene). The ViraTech UV-400 unit provides a viable option for health care facilities struggling to cope with the growing problem of multidrug resistant organisms and this technology can serve as an adjunct to existing infection management procedures and disinfection protocols wherever the potential exists for microorganisms to spread by the airborne route."
"Our Company receives reports from around the world on an almost daily basis about the growing problems connected with the spread of these increasingly drug resistant bacterial strains," said Jack Lennon, President of UV Flu Technologies. "Antibiotics have become so pervasive in today's medical therapies, that not only are they becoming less effective, but their overuse is increasingly being considered as part of the problem. Drug-resistant superbugs have now been found in 20 states, as well as worldwide, and when they hit the critically ill, they can be fatal 30-60% of the time. In one recent incident at an infant ward at the University College Hospital in London, 15 babies in the unit were found to be carrying several types of bacteria, including 13 who had bacterial superbugs resistant to treatment. Of four babies seriously infected, one survived."
"So that the public can participate in actions to help reduce the spread of these strains, the Company has committed to advertising, including television and other media in order to educate consumers and to offer help where needed," said Mr. Lennon. "We are looking to develop a plan to offer our UV-400 indoor air quality units either free or at significantly discounted costs to those schools and hospitals that suffer from serious outbreaks. We hope to partner with institutions which are genuinely interested in working with us in order to develop an action plan for their facilities. For those with respiratory problems or weakened immune systems, hospital or institution acquired bacterial infections can prove deadly. We believe our product delivers an immediate, effective and proven ability to kill at least 99% of airborne bacteria thereby reducing the risk of infection."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT - News)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
"Superbugs may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant"- Dr. Wladyslaw Jan Kowalski, PE, Phd
CENTERVILLE, MA--(Investorideas.com newswire ) - UV Flu Technologies, Inc. (OTC.BB:UVFT ) reports that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
Dr. Wladyslaw Jan Kowalski, PE, Phd, a world leading expert on the bacteria killing efficacy of ultraviolet light, recently commented on the UV-400: "Ultraviolet germicidal irradiation (UVGI) destroys bacteria by damaging the nucleic acids and thereby preventing reproduction. Multidrug-resistant microbes (superbugs) may have resistance to antibiotics but they remain as susceptible to ultraviolet radiation as any normal bacteria variant. The number of multidrug resistant microbes has been increasing, apparently due to overuse of antibiotics and other factors, and is expected to pose a serious challenge to health care facilities in the future as treatment options diminish."
Dr. Kowalski further added, "The ViraTech UV-400 model air cleaner has a demonstrated ability to disinfect air and inactivate a wide range of bacterial pathogens including Staphylococcus aureus (MRSA), Pseudomonas, and Klebsiella as has been conclusively demonstrated in independent laboratory tests. The UV-400 produces a germicidal UV exposure dose of 41 J/m(2), as independently verified by biodosimetric testing, which is sufficient to reduce pathogenic bacterial populations by at least 99%. This disinfection rate will apply regardless of the multidrug resistance of bacteria such as those that may contain the NDM-1 enzyme (the superbug gene). The ViraTech UV-400 unit provides a viable option for health care facilities struggling to cope with the growing problem of multidrug resistant organisms and this technology can serve as an adjunct to existing infection management procedures and disinfection protocols wherever the potential exists for microorganisms to spread by the airborne route."
"Our Company receives reports from around the world on an almost daily basis about the growing problems connected with the spread of these increasingly drug resistant bacterial strains," said Jack Lennon, President of UV Flu Technologies. "Antibiotics have become so pervasive in today's medical therapies, that not only are they becoming less effective, but their overuse is increasingly being considered as part of the problem. Drug-resistant superbugs have now been found in 20 states, as well as worldwide, and when they hit the critically ill, they can be fatal 30-60% of the time. In one recent incident at an infant ward at the University College Hospital in London, 15 babies in the unit were found to be carrying several types of bacteria, including 13 who had bacterial superbugs resistant to treatment. Of four babies seriously infected, one survived."
"So that the public can participate in actions to help reduce the spread of these strains, the Company has committed to advertising, including television and other media in order to educate consumers and to offer help where needed," said Mr. Lennon. "We are looking to develop a plan to offer our UV-400 indoor air quality units either free or at significantly discounted costs to those schools and hospitals that suffer from serious outbreaks. We hope to partner with institutions which are genuinely interested in working with us in order to develop an action plan for their facilities. For those with respiratory problems or weakened immune systems, hospital or institution acquired bacterial infections can prove deadly. We believe our product delivers an immediate, effective and proven ability to kill at least 99% of airborne bacteria thereby reducing the risk of infection."
Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.
About UV Flu Technologies, Inc. (OTC.BB:UVFT - News)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Contact:
Investor Information:Geaux IR Services, Inc.Toll-Free: 1-888-355-8838
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Trading Alert: Biotech Stocks To Watch; (OTCBB: UVFT), (OTCBB: KBLB), (NASDAQ:AMGN), (NYSE:ELN)
Trading Alert: Biotech Stocks To Watch; (OTCBB: UVFT), (OTCBB: KBLB), (NASDAQ:AMGN), (NYSE:ELN)
Point Roberts, WA - September 24, 2010 (Investorideas.com Newswire) - InvestorIdeas.com, leader in sector research for investors, reports on recent Biotech/ Healthcare Stocks news and trading for September 24th.
Biotech Stocks include UV Flu Technologies, Inc., (OTCBB: UVFT), Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), Amgen Inc. (NASDAQ:AMGM), and Elan Corp. plc (NYSE: ELN)
Sector Snapshot: (Trading at time or release)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.31, up 0.01 (3.33%)
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), trading at $ 0. 2145, up 0.0630 (41.58%) on Volume of 20,704,335 shares
Amgen Inc. (NASDAQ:AMGN), trading at $ 56.10, up 0.38 (0.68%)
Elan Corp. plc NYSE:ELN) trading at $ 5.42, up 0.30 (5.86%)
Biotech Stocks to Watch News
UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
The company recently announced that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
The U.S. CDC has described antibiotic resistance as “one of the world’s most pressing health problems” as “the number of bacteria resistant to antibiotics has increased in the last decade [and] … many bacterial infections are becoming resistant to the most commonly prescribed antibiotic treatments.” The World Health Organization (WHO) has identified antibiotic resistance as “one of the three greatest threats to human health.” Source : http://www.idsociety.org/10x20.htm
Latest News:
“UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce that the company and its flagship UV-400 air purification system will be featured on a segment of the “Designing Spaces” TV Show, to be aired nationally during the 4th quarter. The show, to be aired on the Women’s Entertainment channel, is scheduled for the holiday season and is expected to reach up to 75 million households.”
Website: http://www.uvflutech.com/
UV Flu Technologies, Inc., Key Highlights
• FDA Approved as a Class II Medical device
• Extensive testing by EPA and FDA certified laboratories
confirm the proprietary system has over 99% effectiveness of eliminating bacteria
• The Company’s strategic differentiators include excellent independent test
results proving the effectiveness and safety of its products, proprietary design,
and FDA market clearance approving the sale of its products as medical
devices.
• The Company has been issued U.S. Patent No. 6939397 with 43 claims covering
its innovative removable cartridge, housing, UV chamber, UV radiation
source and baffle technology.
• UV Flu’s products are environmentally friendly. The energy efficient system
does not use or produce ozone, uses less energy than a 100 watt light bulb
and can qualify for Green Building programs.
• Experts have warned that a new type of drug-resistant superbug is emerging.
NDM-1 is a gene carried by bacteria that makes the strain resistant to some of
the most powerful antibiotics. NDM-1 can easily now jump from one strain of
bacteria to another.
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB)
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) Recent News: “Kraig Biocraft Laboratories, Inc. is very pleased to announce that the University of Notre Dame and Kraig Biocraft Laboratories will hold a joint press conference Wednesday, September 29, 2010 on the Notre Dame campus to describe a new research breakthrough and its possible biomedical and commercial applications.”
Full Article: http://finance.yahoo.com/news/University-of-Notre-Dame-and-iw-1958169015.html?x=0&.v=1
About Kraig Biocraft Laboratories, Inc: is a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including spider silk. Our work is focused on the development of spider silk and other high strength polymers that we believe have the potential for significant industrial and consumer applications. http://www.kraiglabs.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About our Biotech investor portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA - September 24, 2010 (Investorideas.com Newswire) - InvestorIdeas.com, leader in sector research for investors, reports on recent Biotech/ Healthcare Stocks news and trading for September 24th.
Biotech Stocks include UV Flu Technologies, Inc., (OTCBB: UVFT), Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), Amgen Inc. (NASDAQ:AMGM), and Elan Corp. plc (NYSE: ELN)
Sector Snapshot: (Trading at time or release)
UV Flu Technologies, Inc., (OTCBB: UVFT) trading at $ 0.31, up 0.01 (3.33%)
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), trading at $ 0. 2145, up 0.0630 (41.58%) on Volume of 20,704,335 shares
Amgen Inc. (NASDAQ:AMGN), trading at $ 56.10, up 0.38 (0.68%)
Elan Corp. plc NYSE:ELN) trading at $ 5.42, up 0.30 (5.86%)
Biotech Stocks to Watch News
UV Flu Technologies, Inc., (OTCBB: UVFT) Key Highlights and Recent Press
UV Flu Technologies, Inc., (OTCBB: UVFT) is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. UV Flu is committed to providing clean air to improve health and prevent the spread of disease.
The company recently announced that in response to recent outbreaks of drug resistant superbugs such as NDM-1, and persistent occurrences of highly contagious strains of bacteria such as MRSA, the Company is implementing a national campaign to inform the public how its ViraTech UV-400 indoor air purifier significantly helps reduce exposure risks.
The U.S. CDC has described antibiotic resistance as “one of the world’s most pressing health problems” as “the number of bacteria resistant to antibiotics has increased in the last decade [and] … many bacterial infections are becoming resistant to the most commonly prescribed antibiotic treatments.” The World Health Organization (WHO) has identified antibiotic resistance as “one of the three greatest threats to human health.” Source : http://www.idsociety.org/10x20.htm
Latest News:
“UV Flu Technologies, Inc. (OTCBB: UVFT) (the “Company”) is pleased to announce that the company and its flagship UV-400 air purification system will be featured on a segment of the “Designing Spaces” TV Show, to be aired nationally during the 4th quarter. The show, to be aired on the Women’s Entertainment channel, is scheduled for the holiday season and is expected to reach up to 75 million households.”
Website: http://www.uvflutech.com/
UV Flu Technologies, Inc., Key Highlights
• FDA Approved as a Class II Medical device
• Extensive testing by EPA and FDA certified laboratories
confirm the proprietary system has over 99% effectiveness of eliminating bacteria
• The Company’s strategic differentiators include excellent independent test
results proving the effectiveness and safety of its products, proprietary design,
and FDA market clearance approving the sale of its products as medical
devices.
• The Company has been issued U.S. Patent No. 6939397 with 43 claims covering
its innovative removable cartridge, housing, UV chamber, UV radiation
source and baffle technology.
• UV Flu’s products are environmentally friendly. The energy efficient system
does not use or produce ozone, uses less energy than a 100 watt light bulb
and can qualify for Green Building programs.
• Experts have warned that a new type of drug-resistant superbug is emerging.
NDM-1 is a gene carried by bacteria that makes the strain resistant to some of
the most powerful antibiotics. NDM-1 can easily now jump from one strain of
bacteria to another.
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB)
Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) Recent News: “Kraig Biocraft Laboratories, Inc. is very pleased to announce that the University of Notre Dame and Kraig Biocraft Laboratories will hold a joint press conference Wednesday, September 29, 2010 on the Notre Dame campus to describe a new research breakthrough and its possible biomedical and commercial applications.”
Full Article: http://finance.yahoo.com/news/University-of-Notre-Dame-and-iw-1958169015.html?x=0&.v=1
About Kraig Biocraft Laboratories, Inc: is a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including spider silk. Our work is focused on the development of spider silk and other high strength polymers that we believe have the potential for significant industrial and consumer applications. http://www.kraiglabs.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About our Biotech investor portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
C Van Zant: 800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Biotech News: UV Flu Technologies (OTCBB: UVFT) Air Purification System Airing on “The Designing Spaces/ Holiday Spaces” TV Show
Biotech News: UV Flu Technologies (OTCBB: UVFT) Air Purification System Airing on “The Designing Spaces/ Holiday Spaces” TV Show
Show expects to reach up to 75 million households
CENTERVILLE, MA – (Investorideas.com Newswire ) – September 24, 2010) – Biotechnology Products company , UV Flu Technologies, Inc. (OTCBB: UVFT) reports the company's UV-400 air purification system will be featured on a segment of the “Designing Spaces” TV Show, to be aired nationally during the 4th quarter. The show, to be aired on the Women’s Entertainment channel, is scheduled for the holiday season and is expected to reach up to 75 million households.
“We are thrilled to be working with Designing Spaces as part of this Holiday Show,” said Jack Lennon, President of UV Flu Technologies. “The theme of the segment will be how to stay healthy indoors over the holidays, and our product fits perfectly within this theme. Our ViraTech UV-400, has been laboratory proven to kill airborne bacteria and other contaminants, including odors and volatile organic compounds. There are hundreds of compounds, such as formaldehyde, acetone, benzene, etc… that can be found in the average home and which can cause severe respiratory problems.”
Mr. Lennon further stated “These compounds are regularly found in furniture, cleaning supplies, building materials, insecticides, and even common household items like hairspray. With families spending over 90% of their time indoors, particularly with the proliferation of indoor home theaters and computer games, the public is susceptible to increased risks of exposure or transmission of serious illnesses during the holidays. We hope to educate people to the many dangers associated with poor indoor air quality, and that our UV-400 is a very cost-effective ways to protect themselves. We believe this show will provide a tremendous platform to reach one of our key target markets; parents concerned with the health of their families.”
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Show expects to reach up to 75 million households
CENTERVILLE, MA – (Investorideas.com Newswire ) – September 24, 2010) – Biotechnology Products company , UV Flu Technologies, Inc. (OTCBB: UVFT) reports the company's UV-400 air purification system will be featured on a segment of the “Designing Spaces” TV Show, to be aired nationally during the 4th quarter. The show, to be aired on the Women’s Entertainment channel, is scheduled for the holiday season and is expected to reach up to 75 million households.
“We are thrilled to be working with Designing Spaces as part of this Holiday Show,” said Jack Lennon, President of UV Flu Technologies. “The theme of the segment will be how to stay healthy indoors over the holidays, and our product fits perfectly within this theme. Our ViraTech UV-400, has been laboratory proven to kill airborne bacteria and other contaminants, including odors and volatile organic compounds. There are hundreds of compounds, such as formaldehyde, acetone, benzene, etc… that can be found in the average home and which can cause severe respiratory problems.”
Mr. Lennon further stated “These compounds are regularly found in furniture, cleaning supplies, building materials, insecticides, and even common household items like hairspray. With families spending over 90% of their time indoors, particularly with the proliferation of indoor home theaters and computer games, the public is susceptible to increased risks of exposure or transmission of serious illnesses during the holidays. We hope to educate people to the many dangers associated with poor indoor air quality, and that our UV-400 is a very cost-effective ways to protect themselves. We believe this show will provide a tremendous platform to reach one of our key target markets; parents concerned with the health of their families.”
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. VIRATECH UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Disclaimer: The following news is paid for by third party on behalf of UV Flu Technologies, Inc., (eight hundred) Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
More Investorideas Biotech Stocks info wwww.BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Thursday, September 23, 2010
Biotech/Pharma stocks; Anthera Pharmaceuticals (Nasdaq: ANTH) Announces Pricing of $31.5 Million PIPE Financing
Anthera Pharmaceuticals (Nasdaq: ANTH) Announces Pricing of $31.5 Million PIPE Financing
HAYWARD, Calif., (http://www.investorideas.com/ biotech stocks blog ) )- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has entered into definitive agreements with certain accredited investors in connection with a private placement, or PIPE, financing transaction pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. Upon the closing of the transaction, Anthera will receive gross proceeds of approximately $31.5 million in exchange for the issuance to such investors of 10,500,000 units, with each unit consisting of one share of Anthera common stock and one warrant to purchase 0.40 shares of Anthera common stock. The warrants will be exercisable for a period of five years from the date of their issuance at an exercise price of $3.30 per share. The closing of the transaction, which is subject to customary closing conditions, is scheduled to occur on or prior to September 24, 2010. Anthera intends to use the net proceeds of the transaction to fund the previously announced expansion of Anthera's A-623 Phase 2b study, known as PEARL-SC (A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A-623 AdministRation in Subjects with Systemic Lupus Erythematosus), the manufacture of Phase 3 material for A-623, and for general corporate purposes.
Piper Jaffray & Co. served as sole lead placement agent and Wedbush PacGrow Life Sciences served as co-placement agent for the transaction.
Following the completion of the transaction, Anthera expects that its Board of Directors will appoint Peter Thompson, M.D. to the Board of Directors. Dr. Thompson is currently a Venture Partner with OrbiMed Advisors, LLC and has over 20 years of industry experience. He co-founded Trubion Pharmaceuticals, and served as CEO and Chairman from its inception through its IPO on NASDAQ and as a public company until his retirement in 2009. Dr. Thompson is the former Vice President and General Manager of Chiron Informatics at Chiron Corporation and held various executive positions at Becton Dickinson, including Vice President Research and Technology Department of BD Bioscience. Dr. Thompson is a co-founder of iMetrikus, a clinical decision support company, where he served as CEO and Chairman. He is the founder and Managing Director of Strategicon Partners, an investment and management services company. He serves as a Director of Response Biomedical and CoDa Therapeutics. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, a board-certified internist and oncologist, and was on staff at the National Cancer Institute following his internal medicine training at Yale University.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. Anthera has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock, including the shares of common stock issuable upon exercise of the warrants, sold in the private placement. Anthera has agreed to file the registration statement within 30 days of the closing of the private placement. If any shares are unable to be included on the initial registration statement, Anthera has agreed to file subsequent registration statements until all the shares have been registered, and the registration rights agreement imposes certain customary cash penalties on Anthera for its failure to satisfy specified filing and effectiveness time periods.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (or BAFF, or BLyS), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include statements relating to whether and when the private placement will close, Anthera's anticipated uses of the net proceeds of the transaction and whether and when Anthera's Board of Directors will appoint Dr. Peter Thompson to Anthera's Board of Directors. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Juliane Snowden of Burns McClellan, Inc., jsnowden@burnsmc.com or 212.213.0006.
SOURCE Anthera Pharmaceuticals, Inc.
More Investorideas Biotech Stocks info
BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
HAYWARD, Calif., (http://www.investorideas.com/ biotech stocks blog ) )- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has entered into definitive agreements with certain accredited investors in connection with a private placement, or PIPE, financing transaction pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. Upon the closing of the transaction, Anthera will receive gross proceeds of approximately $31.5 million in exchange for the issuance to such investors of 10,500,000 units, with each unit consisting of one share of Anthera common stock and one warrant to purchase 0.40 shares of Anthera common stock. The warrants will be exercisable for a period of five years from the date of their issuance at an exercise price of $3.30 per share. The closing of the transaction, which is subject to customary closing conditions, is scheduled to occur on or prior to September 24, 2010. Anthera intends to use the net proceeds of the transaction to fund the previously announced expansion of Anthera's A-623 Phase 2b study, known as PEARL-SC (A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A-623 AdministRation in Subjects with Systemic Lupus Erythematosus), the manufacture of Phase 3 material for A-623, and for general corporate purposes.
Piper Jaffray & Co. served as sole lead placement agent and Wedbush PacGrow Life Sciences served as co-placement agent for the transaction.
Following the completion of the transaction, Anthera expects that its Board of Directors will appoint Peter Thompson, M.D. to the Board of Directors. Dr. Thompson is currently a Venture Partner with OrbiMed Advisors, LLC and has over 20 years of industry experience. He co-founded Trubion Pharmaceuticals, and served as CEO and Chairman from its inception through its IPO on NASDAQ and as a public company until his retirement in 2009. Dr. Thompson is the former Vice President and General Manager of Chiron Informatics at Chiron Corporation and held various executive positions at Becton Dickinson, including Vice President Research and Technology Department of BD Bioscience. Dr. Thompson is a co-founder of iMetrikus, a clinical decision support company, where he served as CEO and Chairman. He is the founder and Managing Director of Strategicon Partners, an investment and management services company. He serves as a Director of Response Biomedical and CoDa Therapeutics. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, a board-certified internist and oncologist, and was on staff at the National Cancer Institute following his internal medicine training at Yale University.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. Anthera has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock, including the shares of common stock issuable upon exercise of the warrants, sold in the private placement. Anthera has agreed to file the registration statement within 30 days of the closing of the private placement. If any shares are unable to be included on the initial registration statement, Anthera has agreed to file subsequent registration statements until all the shares have been registered, and the registration rights agreement imposes certain customary cash penalties on Anthera for its failure to satisfy specified filing and effectiveness time periods.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator (or BAFF, or BLyS), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include statements relating to whether and when the private placement will close, Anthera's anticipated uses of the net proceeds of the transaction and whether and when Anthera's Board of Directors will appoint Dr. Peter Thompson to Anthera's Board of Directors. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
CONTACT: Juliane Snowden of Burns McClellan, Inc., jsnowden@burnsmc.com or 212.213.0006.
SOURCE Anthera Pharmaceuticals, Inc.
More Investorideas Biotech Stocks info
BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks, Biotech, Pharma and Industry News and Biotech Investor Research Tools including a Biotech Stocks Directory
Wednesday, September 22, 2010
Investorideas.com - Actively Trading Pharma/Biotech Stocks: OTCVolumeleaders.com Reports on OTCBB Market ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: BOPH), (OTCBB: ACCP), (OTCBB: QPSA)
Investorideas.com - Actively Trading Pharma/Biotech Stocks: OTCVolumeleaders.com Reports on OTCBB Market ($2.00-$5.00): (OTCBB: KMKCF), (OTCBB: BOPH), (OTCBB: ACCP), (OTCBB: QPSA)
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) September 22, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include CONTINENTAL MINERALS (OTCBB: KMKCF), Bohai Pharmaceuticals Group, Inc. (OTCBB: BOPH), Access Pharmaceuticals Inc. (OTCBB: ACCP), and Quepasa Corp. (OTCBB: QPSA).
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
OTC/Market Commentary:
One of the OTCBB volume leader reports; Recent News: "Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. Coinciding with the signing of the above agreement, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals ("Jian An") Limited in Shenzhen, China in an effort to leverage Jian An's extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan."
Full Article: http://finance.yahoo.com/news/Access-Pharmaceuticals-Inc-prnews-1403730987.html?x=0&.v=1
Market Snapshot: (at time of release)
Dow 10,746.39 -14.64 -0.14%
Nasdaq 2,333.63 -15.72 -0.67%
S&P 500 1,135.01 -4.77 -0.42%
10 Yr Bond(%) 2.5480% -0.4600
Oil 74.69 -0.28 -0.37%
Gold 1,290.00 +17.60 +1.38%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/
Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC
Investors - Get OTC stock quotes from http://www.otcmarkets.com
Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) September 22, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include CONTINENTAL MINERALS (OTCBB: KMKCF), Bohai Pharmaceuticals Group, Inc. (OTCBB: BOPH), Access Pharmaceuticals Inc. (OTCBB: ACCP), and Quepasa Corp. (OTCBB: QPSA).
Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
OTC/Market Commentary:
One of the OTCBB volume leader reports; Recent News: "Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. Coinciding with the signing of the above agreement, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals ("Jian An") Limited in Shenzhen, China in an effort to leverage Jian An's extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan."
Full Article: http://finance.yahoo.com/news/Access-Pharmaceuticals-Inc-prnews-1403730987.html?x=0&.v=1
Market Snapshot: (at time of release)
Dow 10,746.39 -14.64 -0.14%
Nasdaq 2,333.63 -15.72 -0.67%
S&P 500 1,135.01 -4.77 -0.42%
10 Yr Bond(%) 2.5480% -0.4600
Oil 74.69 -0.28 -0.37%
Gold 1,290.00 +17.60 +1.38%
OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/
Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
* Attention Investors in British Columbia Canada: Do not subscribe to any OTC stocks not currently filing with Sedar in BC and BC Securities
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC
Investors - Get OTC stock quotes from http://www.otcmarkets.com
Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Subscribe to:
Posts (Atom)